Posted by Michael Wonder on 04 Nov 2022
Apellis announces plans to submit 24 month Phase 3 data to the FDA for pegcetacoplan NDA for geographic atrophy
3 November 2022 - Submission will be a major amendment to the new drug application, extending the review period by three months with an expected PDUFA target action date in February 2023.
Apellis Pharmaceuticals today provided an update on its new drug application for intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration.
